주요서비스 바로가기
본문 바로가기
매체정보 바로가기
로그인 바로가기
기사검색 바로가기
전체서비스 바로가기
상단영역
UPDATE : 2024-04-19 17:10 (Fri)
Home
Log in
Join
전체메뉴
기사검색
검색
본문영역
All articles
목록
(
총 :
170 )
기사목록 보기 형태
제목형
요약형
포토형
‘CPhI Korea thriving on local firms’ zeal for drug export’
Jeong Sae-im
2019.08.08 14:01
[Reporter’s Notebook] SillaJen should be ashamed of itself
Jeong Sae-im
2019.08.07 12:57
HLB to seek pre-NDA meeting with FDA for rivoceranib
Jeong Sae-im
2019.08.06 14:16
SillaJen remains confident about Pexa-Vec’s value, despite trial failure
Jeong Sae-im
2019.08.05 14:45
Suspicions resurge over SillaJen execs’ stock selling before Pexa-Vec trial suspension
Jeong Sae-im
2019.08.05 11:22
Biotech shares tank amid SillaJen’s likely halt of Pexa-Vec trial
Jeong Sae-im
2019.08.02 14:39
Eutilex pipelines are underrated: CEO
Jeong Sae-im
2019.08.01 15:34
Biotech industry group urges Japan to withdraw export curbs
Jeong Sae-im
2019.07.25 17:05
[Focus] Korean biopharmas eye US Humira market
Jeong Sae-im
2019.07.25 14:59
Korean drugs strong in anti-reflux treatment market
Jeong Sae-im
2019.07.22 15:13
MedPacto passes tech assessment, seeks KOSDAQ listing this year
Jeong Sae-im
2019.07.19 16:59
Biopharmaceutical stocks face grim outlook in 2H
Jeong Sae-im
2019.07.17 14:09
처음
이전
이전
이전
11
12
13
14
15
끝
위로
전체메뉴
All
Hospital
Pharma
Bio
All
Korea‘s Bio Industry
Device/ICT
Policy
People
Life science
Special
All
Innovation for Survival
Korea’s medical culture series
Korea’s New Candidate Drug Watch List
Special Series in Celebration of KBR's 1st Anniversary
Interview with foreign envoys
Special Series in Celebration of KBR’s 2nd Anniversary
Interview with global pharma
Special Series in Celebration of KBR’s 3rd Anniversary
ASCO 2020 Highlights
Special Series in Celebration of KBR’s 4th Anniversary
KBR Covering RSNA 2021
Special Series in Celebration of KBR’s 5th Anniversary
Special Report on EULAR 2022
[Top K-Pharma Analysis]
BIO 2023
Opinion
All
Reporter’s Notebook
Journalist’s Column
Congratulatory Remarks
Sponsored
전체메뉴닫기